{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:09:30Z","timestamp":1791425370405,"version":"4.3.3"},"reference-count":46,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The activator protein 1 (AP-1) member JunB has recently been implicated in leukemogenesis. Here we surveyed human lymphoma samples for expression of JunB and other AP-1 members (c-Jun, c-Fos, Fra1, JunD). JunB was strongly expressed in T-cell lymphomas, but non-Hodgkin B-cell lymphomas do not or only weakly express JunB. We therefore asked whether JunB acted as a negative regulator of B-cell development, proliferation, and transformation. We used transgenic mice that expressed JunB under the control of the ubiquitin C promoter; these displayed increased JunB levels in both B- and T-lymphoid cells. JunB transgenic cells of B-lymphoid, but not of T-lymphoid, origin responded poorly to mitogenic stimuli. Furthermore, JunB transgenic cells were found to be less susceptible to the transforming potential of the Abelson oncogene in vitro. In addition, overexpression of JunB partially protected transgenic mice against the oncogenic challenge in vivo. However, transformed B cells eventually escaped from the inhibitory effect of JunB: the proliferative response was similar in explanted tumor-derived cells from transgenic animals and those from wild-type controls. Our results identify JunB as a novel regulator of B-cell proliferation and transformation. (Blood. 2003;102:4159-4165)<\/jats:p>","DOI":"10.1182\/blood-2003-03-0915","type":"journal-article","created":{"date-parts":[[2003,8,11]],"date-time":"2003-08-11T22:36:54Z","timestamp":1060641414000},"page":"4159-4165","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":77,"title":["JunB inhibits proliferation and transformation in B-lymphoid cells"],"prefix":"10.1182","volume":"102","author":[{"given":"Agnieszka P.","family":"Szremska","sequence":"first","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kenner","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Weisz","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene G.","family":"Ott","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Passegue\u0301","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Artwohl","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Freissmuth","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Stoxreiter","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christian","family":"Theussl","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina Baumgartner","family":"Parzer","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moriggl","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin F.","family":"Wagner","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Sexl","sequence":"additional","affiliation":[{"name":"From the Institute of Pharmacology, Vienna University, Austria; Institute of Molecular Pathology (IMP), Vienna, Austria; and Department of Endocrinology, Vienna University Clinics, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222041708900_REF1","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization Classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology. 2000;36: 69-86.","DOI":"10.1046\/j.1365-2559.2000.00895.x"},{"key":"2020021222041708900_REF2","doi-asserted-by":"crossref","unstructured":"Theodossiou C, Schwarzenberger P. Non-Hodgkin's lymphomas. Clin Obstet Gynecol. 2002;45: 820-829.","DOI":"10.1097\/00003081-200209000-00029"},{"key":"2020021222041708900_REF3","doi-asserted-by":"crossref","unstructured":"Vasanwala FH, Kusam S, Toney LM, Dent AL. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol. 2002;169: 1922-1929.","DOI":"10.4049\/jimmunol.169.4.1922"},{"key":"2020021222041708900_REF4","doi-asserted-by":"crossref","unstructured":"Arnulf B, Villemain A, Nicot C, et al. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood. 2002;100: 4129-4138.","DOI":"10.1182\/blood-2001-12-0372"},{"key":"2020021222041708900_REF5","unstructured":"Mori N, Fujii M, Iwai K, et al. Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells. Blood. 2000;95: 3915-3921."},{"key":"2020021222041708900_REF6","doi-asserted-by":"crossref","unstructured":"Wellmann A, Doseeva V, Butscher W, et al. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. FASEB J. 1997;11: 965-972.","DOI":"10.1096\/fasebj.11.12.9337149"},{"key":"2020021222041708900_REF7","doi-asserted-by":"crossref","unstructured":"Jochum W, Passegue\u0301 E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene. 2001;20: 2401-2412.","DOI":"10.1038\/sj.onc.1204389"},{"key":"2020021222041708900_REF8","doi-asserted-by":"crossref","unstructured":"Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20: 2390-2400.","DOI":"10.1038\/sj.onc.1204383"},{"key":"2020021222041708900_REF9","doi-asserted-by":"crossref","unstructured":"Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4: E131-E136.","DOI":"10.1038\/ncb0502-e131"},{"key":"2020021222041708900_REF10","doi-asserted-by":"crossref","unstructured":"Johnson R, Spiegelman B, Hanahan D, Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol. 1996;16: 4504-4511.","DOI":"10.1128\/MCB.16.8.4504"},{"key":"2020021222041708900_REF11","doi-asserted-by":"crossref","unstructured":"Behrens A, Jochum W, Sibilia M, Wagner EF. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene. 2000;19: 2657-2663.","DOI":"10.1038\/sj.onc.1203603"},{"key":"2020021222041708900_REF12","doi-asserted-by":"crossref","unstructured":"Eferl R, Ricci R, Kenner L, et al. Liver tumor development: c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003;112: 181-192.","DOI":"10.1016\/S0092-8674(03)00042-4"},{"key":"2020021222041708900_REF13","doi-asserted-by":"crossref","unstructured":"Smith LM, Wise SC, Hendricks DT, et al. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999;18: 6063-6070.","DOI":"10.1038\/sj.onc.1202989"},{"key":"2020021222041708900_REF14","doi-asserted-by":"crossref","unstructured":"Battista S, de Nigris F, Fedele M, et al. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene. 1998;17: 377-385.","DOI":"10.1038\/sj.onc.1201953"},{"key":"2020021222041708900_REF15","doi-asserted-by":"crossref","unstructured":"Bamberger AM, Milde-Langosch K, Rossing E, Goemann C, Loning T. Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J Cancer Res Clin Oncol. 2001;127: 545-550.","DOI":"10.1007\/s004320100255"},{"key":"2020021222041708900_REF16","doi-asserted-by":"crossref","unstructured":"Deng T, Karin M. JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes Dev. 1993;7: 479-490.","DOI":"10.1101\/gad.7.3.479"},{"key":"2020021222041708900_REF17","unstructured":"Hsu JC, Cressman DE, Taub R. Promoter-specific trans-activation and inhibition mediated by JunB. Cancer Res. 1993;53: 3789-3794."},{"key":"2020021222041708900_REF18","doi-asserted-by":"crossref","unstructured":"Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000;19: 2056-2068.","DOI":"10.1093\/emboj\/19.9.2056"},{"key":"2020021222041708900_REF19","doi-asserted-by":"crossref","unstructured":"Szabowski A, Maas-Szabowski N, Andrecht S, et al. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell. 2000;103: 745-755.","DOI":"10.1016\/S0092-8674(00)00178-1"},{"key":"2020021222041708900_REF20","doi-asserted-by":"crossref","unstructured":"Passegue\u0301 E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J. 2000;19: 2969-2979.","DOI":"10.1093\/emboj\/19.12.2969"},{"key":"2020021222041708900_REF21","doi-asserted-by":"crossref","unstructured":"Schorpp-Kistner M, Wang ZQ, Angel P, Wagner EF. JunB is essential for mammalian placentation. EMBO J. 1999;18: 934-948.","DOI":"10.1093\/emboj\/18.4.934"},{"key":"2020021222041708900_REF22","doi-asserted-by":"crossref","unstructured":"Schorpp M, Ja\u0308ger R, Schellander K, et al. The human ubiquitin C promoter directs high ubiqitous expression of transgenes in mice. Nucleic Acids Res. 1996;24: 1787-1788.","DOI":"10.1093\/nar\/24.9.1787"},{"key":"2020021222041708900_REF23","doi-asserted-by":"crossref","unstructured":"Finch S, Joseloff E, Bowden T. JunB negatively regulates AP-1 activity and cell proliferation of malignant mouse keratinocytes. J Cancer Res Clin Oncol. 2002;128: 3-10.","DOI":"10.1007\/s00432-001-0298-x"},{"key":"2020021222041708900_REF24","doi-asserted-by":"crossref","unstructured":"Passegue\u0301 E, Jochum W, Schorpp-Kistner M, Mo\u0308hle-Steinlein U, Wagner EF. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage. Cell. 2001;104: 21-32.","DOI":"10.1016\/S0092-8674(01)00188-X"},{"key":"2020021222041708900_REF25","doi-asserted-by":"crossref","unstructured":"Yang MY, Liu TC, Chang JG, Lin PM, Lin SF. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood. 2003;101: 3205-3211.","DOI":"10.1182\/blood-2002-05-1598"},{"key":"2020021222041708900_REF26","doi-asserted-by":"crossref","unstructured":"Bossy-Wetzel E, Bravo R, Hanahan D. Transcription factors junB and c-jun are selectively up-regulated and functionally implicated in fibrosarcoma development. Genes Dev. 1992;6: 2340-2351.","DOI":"10.1101\/gad.6.12a.2340"},{"key":"2020021222041708900_REF27","doi-asserted-by":"crossref","unstructured":"Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappaB. EMBO J. 2002;21: 4104-4113.","DOI":"10.1093\/emboj\/cdf389"},{"key":"2020021222041708900_REF28","doi-asserted-by":"crossref","unstructured":"Sexl V, Sherr CJ, Beach D, Roussel M. A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene. 1999;18: 573-582.","DOI":"10.1038\/sj.onc.1202362"},{"key":"2020021222041708900_REF29","doi-asserted-by":"crossref","unstructured":"Cordell J, Falini B, Erber ON, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984;32: 219-229.","DOI":"10.1177\/32.2.6198355"},{"key":"2020021222041708900_REF30","doi-asserted-by":"crossref","unstructured":"Sexl V, Piekorz R, Moriggl R, et al. Stat5a\/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr\/abl-induced transformation are independent of stat5. Blood. 2000;96: 2277-2283.","DOI":"10.1182\/blood.V96.6.2277"},{"key":"2020021222041708900_REF31","doi-asserted-by":"crossref","unstructured":"Moriggl R, Topham D, Teglund S, et al. Stat5 is required for IL-2 induced cell cycle progression of peripheral T cells. Immunity. 1999;10: 249-259.","DOI":"10.1016\/S1074-7613(00)80025-4"},{"key":"2020021222041708900_REF32","doi-asserted-by":"crossref","unstructured":"Sexl V, Kovacic B, Piekorz R, et al. Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood. 2003;101: 4937-4943.","DOI":"10.1182\/blood-2001-11-0142"},{"key":"2020021222041708900_REF33","doi-asserted-by":"crossref","unstructured":"Zindy F, Quelle DE, Roussel M, Sherr CJ. Expression of the p16\/INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene. 1997;15: 203-211.","DOI":"10.1038\/sj.onc.1201178"},{"key":"2020021222041708900_REF34","doi-asserted-by":"crossref","unstructured":"Rosenberg N, Witte ON. The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res. 1988;39: 39-81.","DOI":"10.1016\/S0065-3527(08)60708-3"},{"key":"2020021222041708900_REF35","doi-asserted-by":"crossref","unstructured":"Gordon MY. Biological consequences of the BCR\/ABL fusion gene in humans and mice. J Clin Pathol. 1999;52: 719-722.","DOI":"10.1136\/jcp.52.10.719"},{"key":"2020021222041708900_REF36","doi-asserted-by":"crossref","unstructured":"Herrlich P. Cross-talk between glucocorticoid receptor and AP-1. Oncogene. 2001;20: 2465-2475.","DOI":"10.1038\/sj.onc.1204388"},{"key":"2020021222041708900_REF37","doi-asserted-by":"crossref","unstructured":"Mechta-Grigoriou F, Gerald D, Yaniv M. The mammalian Jun proteins: redundancy and specificity. Oncogene. 2001;20: 2378-2389.","DOI":"10.1038\/sj.onc.1204381"},{"key":"2020021222041708900_REF38","doi-asserted-by":"crossref","unstructured":"Hartenstein B, Teurich S, Hess J, Schenkel J, Schorpp-Kistner M, Angel P. Th2 cell specific cytokine expression and allergen-induced airway inflammation depend on JunB. EMBO J. 2002;23: 6321-6329.","DOI":"10.1093\/emboj\/cdf648"},{"key":"2020021222041708900_REF39","doi-asserted-by":"crossref","unstructured":"Mao X, Lillington D, Child F, Russell-Jones R, Young B, Whittaker S. Comparative genomic hybridization analysis of primary cutaneous B-cell lymphomas: identification of common genomic alterations in disease pathogenesis. Genes Chromosomes Cancer. 2002;35: 144-155.","DOI":"10.1002\/gcc.10104"},{"key":"2020021222041708900_REF40","doi-asserted-by":"crossref","unstructured":"Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood. 2003;101: 1513-1519.","DOI":"10.1182\/blood-2002-08-2434"},{"key":"2020021222041708900_REF41","doi-asserted-by":"crossref","unstructured":"Kuppers R, Schwering I, Brauninger A, Rajewsky K, Hansmann ML. Biology of Hodgkin's lymphoma. Ann Oncol. 2002;13(suppl 1): 11-18.","DOI":"10.1093\/annonc\/13.S1.11"},{"key":"2020021222041708900_REF42","doi-asserted-by":"crossref","unstructured":"Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med. 2000;191: 207-212.","DOI":"10.1084\/jem.191.2.207"},{"key":"2020021222041708900_REF43","doi-asserted-by":"crossref","unstructured":"Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002;1602: 73-87.","DOI":"10.1016\/S0304-419X(02)00037-9"},{"key":"2020021222041708900_REF44","doi-asserted-by":"crossref","unstructured":"Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1: 222-231.","DOI":"10.1038\/35106065"},{"key":"2020021222041708900_REF45","doi-asserted-by":"crossref","unstructured":"Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene. 2002;21: 3475-3495.","DOI":"10.1038\/sj.onc.1205322"},{"key":"2020021222041708900_REF46","doi-asserted-by":"crossref","unstructured":"Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12: 845-859.","DOI":"10.1038\/sj.leu.2401043"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/12\/4159\/1692547\/h82303004159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/12\/4159\/1692547\/h82303004159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T22:10:18Z","timestamp":1581545418000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/12\/4159\/16741\/JunB-inhibits-proliferation-and-transformation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,1]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-03-0915","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,1]]}}}